...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell cycle >circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis
【24h】

circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis

机译：循环RNA，循环RNA，通过靶向MIR-3918 / BCL2轴来促进肝细胞癌进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Circular (circ)RNA is a special type of endogenous RNA consisting of a covalently closed loop structure without 5 to 3 polarity and a polyadenylated tail. Accumulating evidence suggests that circRNAs play important roles in the development and progression of human cancers. However, the role of circRNAs in the progression of hepatocellular carcinoma (HCC) is largely unknown. This was addressed in the present study using high-throughput sequencing to identify aberrantly expressed circRNAs in HCC patient tissue and cell lines. We found that circ-baculoviral IAP repeat-containing (BIRC)6 was upregulated in HCC tissue samples and cells; this was associated with the overall survival of HCC patients. circ-BIRC6 knockdown reduced HCC cell proliferation, migration, and invasion and enhanced their apoptosis. Additionally, circ-BIRC6 overexpression negatively regulated the expression of microRNA miR-3918, which was identified as an inhibitor of B cell lymphoma (Bcl)2. The tumor-suppressive effect of circ-BIRC6 deletion was abrogated by inhibiting miR-3918. These results indicate that circ-BIRC6 functions as a competing endogenous RNA that regulates Bcl2 expression by sponging miR-3918, and may serve as a prognostic biomarker and therapeutic target for the treatment of HCC.
机译：圆形（循环）RNA是一种特殊类型的内源性RNA，其由具有5至3极性的共价闭合环结构和多腺苷酸化尾部。积累证据表明，Circrnas在人类癌症的开发和进展中起重要作用。然而，Circrnas在肝细胞癌进展中的作用在很大程度上是未知的。在本研究中通过高通量测序解决了这一点，以鉴定HCC患者组织和细胞系中的异常表达的CircrNA。我们发现在HCC组织样品和细胞中上调了含氨杆病毒IAP重复（BIRC）6;这与HCC患者的整体存活有关。电池BIRC6敲低降低HCC细胞增殖，迁移和侵袭，增强其凋亡。另外，循环反应型过表达负调节MicroRNA miR-3918的表达，其被鉴定为B细胞淋巴瘤（Bcl）2的抑制剂。通过抑制miR-3918消除了循环循环抑制效应。这些结果表明，循环BIRC6用作通过冲水MIR-3918调节BCL2表达的竞争内源性RNA，并且可以作为治疗HCC的预后生物标志物和治疗靶标。

著录项

  • 来源
    《Cell cycle》 |2019年第9期|共14页
  • 作者

    Yang Guangsheng; Wang Xin; Liu Bingqi; Lu Zhihua; Xu Zongzhen; Xiu Peng; Liu Zhiqian; Li Jie;

  • 作者单位

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

    Shandong Univ Qilu Hosp Qingdao Dept Gen Surg Qingdao Shandong Peoples R China;

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

    Shandong Univ Qianfoshan Hosp Dept Gen Surg Jinan Shandong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    Circ-BIRC6; miR-3918; Bcl2; hepatocellular carcinoma;

    机译：Circ-Birc6;miR-3918;bcl2;肝细胞癌;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号